Biotech: Setback for Biontech – cancer therapy failed
An mRNA immunotherapy did not halt the progression of head and neck cancer. However, the Mainz researchers do not see this as a definitive end.
Biontech has suffered a setback in cancer research with its vaccine candidate BNT113. The treatment did not significantly extend the survival of patients with a certain form of head and neck cancer without the disease progressing. BNT113 was tested in combination with the antibody Pembrolizumab, also known as Keytruda. The results are another blow to the German biotech company, which has invested heavily in oncology research.
Written by urgent.news from Handelsblatt's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Biotech: Setback for Biontech – cancer therapy failed handelsblatt.com
